Drug intelligence / Profile preview

NBL-030

Development stage: Preclinical
Lead developer: NovaRock Biotherapeutics
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

NBL-030 is a preclinical-stage bispecific antibody developed by NovaRock Biotherapeutics. It is designed to simultaneously target the Interleukin-4 receptor alpha (IL-4Rα) and Interleukin-25 (IL-25) pathways. By dual-targeting these pathways, NBL-030 aims to address Type 2 inflammation and epithelial-derived cytokine signaling, which are key drivers in chronic inflammatory respiratory and skin conditions. The drug is currently being investigated for the potential treatment of asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis.

Targets

IL4R (Interleukin-4 receptor alpha subunit)IL25 (IL-25)

Beyond the preview

Go deeper on NBL-030.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NBL-030.

Explore the full profile